New Phase III data show tiotropium* Respimat® effective across asthma severities
3 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities...